Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Kidney Transplant Recipients

Inclusion Criteria: * Written informed consent obtained before any assessment. * Male or female patient ≥ 18 years old. * Up to date vaccination as per local immunization schedules. * Recipients of a kidney transplant * Recipients of a primary kidney transplant from a heart-beating deceased, living unrelated or non-HLA identical living related donors. Exclusion Criteria: * Multi-organ transplant recipients or prior kidney transplant. * Recipients of an organ from a non-heart beating donor. * Recipient of an organ from an HLA identical living related donor. * ABO incompatible or complement-dependent lymphocytotoxic (CDC) crossmatch positive transplant * Recipients of kidneys from donors who are older than 65 years. * Recipients of kidneys from donors with terminal serum creatinine \> 2 mg/dL. * Patients at high immunological risk for rejection * Patient who is anti-HIV positive, HBsAg-positive or anti-HCV positive (without proof of sustained viral response (SVR) after anti-HCV treatment). * Recipient of a kidney from a donor who tests positive for HIV, HBsAg/HBc positive or HCV. * A negative Epstein Barr virus (EBV) test. * Evidence of advanced liver disease (Child-Pugh C), or any sign of liver decompensation. * Patient with severe systemic infections, current or within the two weeks prior to randomization. * History of malignancy of any organ system, treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or metastases, with the exception of localized excised non-melanomatous skin lesions.